Search clinical trials for: pelacarsen (TQJ230)

Total 10 results

Novartis Pharmaceuticals

Completed

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment

United States
Novartis Pharmaceuticals

Not yet recruiting

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals

Active, not recruiting

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Cardiovascular Disease and Lipoprotein(a)

United States, China, Germany, South Africa, Italy, Spain, Belgium, Czechia, Hungary, Japan, Taiwan, Netherlands, Australia, Austria, Canada, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Argentina, Denmark, Greece, Romani... and more
Novartis Pharmaceuticals

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Aortic Stenosis

Switzerland, Canada, Israel, United States, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

Hyperlipoproteinemia(a)

Germany
Novartis Pharmaceuticals

Recruiting

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) (OLE)

Hyperlipoproteinemia (a)

Germany
University Medical Centre Ljubljana

Withdrawn

Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)

Inflammation | Acute Coronary Syndrome | Lipoproteinemia | Genetic Polymorphisms

Slovenia
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

Healthy Participants

United States
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

Cardiovascular Disease | Elevated Lipoprotein(a)

United States, Canada, Denmark, Germany, Netherlands
Chinese University of Hong Kong

Active, not recruiting

Time-trend Analysis of Clinical Characteristic and Outcomes in Patients With Unprotected Left Main Coronary Artery Disease Treated With PCI Over a 10-year Period (TQJ230)

Cardiovascular Diseases

Hong Kong

3

Subscribe